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Pong-Term Cost-Effectiveness of Clopidogrel
iven for Up to One Year in Patients With Acute
oronary Syndromes Without ST-Segment Elevation
illiam S. Weintraub, MD, FACC,* Elizabeth M. Mahoney, SCD,† Andre Lamy, MD,‡
teven Culler, PHD,* Yong Yuan, PHD,§ Jaime Caro, MD, Sylvie Gabriel, MD,¶
alim Yusuf, MD, FACC,‡ on behalf of the CURE Study Investigators
tlanta, Georgia; Watertown and Concord, Massachusetts; Hamilton, Ontario, Canada; Princeton, New Jersey;
nd Paris, France
OBJECTIVES We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after
an acute coronary syndrome (ACS) without ST-segment elevation.
BACKGROUND The efficacy of platelet inhibition with clopidogrel for up to one year after ACS was
demonstrated in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE)
trial, a randomized trial of 12,562 patients in 28 countries that was conducted between 1998
and 2000. Patients were given clopidogrel (300-mg load followed by 75 mg/day) versus
placebo, both in addition to aspirin, for a mean of nine months.
METHODS We used patient-level clinical outcomes and resource use from the CURE trial and estimates
of life expectancy gains as a result of the prevention of the clinical events of death, stroke, and
myocardial infarction on the basis of data from external sources.
RESULTS Excluding clopidogrel costs, average costs of hospitalizations alone were $325 less for the
clopidogrel arm (95% confidence interval$722 to $45) using diagnosis-related group-based
Medicare reimbursement rates. When including clopidogrel costs ($766 greater for the
clopidogrel arm), average total costs were $442 higher for the clopidogrel arm (95%
confidence interval $62 to $820). The incremental cost-effectiveness ratio (ICER) on the
basis of the Framingham Heart Study was $6,318 per life-year gained (LYG) with
clopidogrel, with 94% of bootstrap-derived ICER estimates $50,000/LYG; based on
Saskatchewan, the ICER was $6,475/LYG with 98% of estimates $50,000.
CONCLUSIONS Platelet inhibition with clopidogrel in patients for up to one year after presentation with an
acute coronary syndrome is both effective and cost-effective. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.051838–45) © 2005 by the American College of Cardiology Foundation
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rhe Clopidogrel in Unstable angina to prevent Recurrent
vents (CURE) trial evaluated the efficacy and safety of
lopidogrel plus aspirin compared with aspirin alone when
nitiated early and continued long term (up to 12 months,
verage of 9 months), in patients presenting with unstable
ngina or a non–ST-segment elevation myocardial infarc-
ion (MI) (1). In CURE, clopidogrel reduced the risk of the
rimary outcome of cardiovascular death, MI, or stroke.
dditionally, there was a reduction in refractory ischemia
eeding urgent intervention, other ischemic events, and
ulmonary edema. A recent study evaluated the cost per
vent prevented with clopidogrel versus placebo on the basis
f in-trial results from the CURE trial (2). To estimate the
ong-term cost-effectiveness of nine months of therapy with
lopidogrel in terms of cost per life-year gained (LYG), it is
ecessary to evaluate the impact of clopidogrel on life
xpectancy. The purpose of the present study is to evaluate
From *Emory University, Atlanta, Georgia; †New England Research Institutes,
atertown, Massachusetts; ‡McMaster University, Hamilton, Ontario, Canada;
Bristol-Myers Squibb, Princeton, New Jersey; Caro Research Institute, Concord,
assachusetts; and ¶Sanofi-Synthelabo, Paris, France. Supported by grants from
anofi-Aventis and Bristol-Myers Squibb to Drs. Weintraub, Caro, and Yusuf. Dr.
uan is an employee of Bristol-Myers Squibb. Dr. Gabriel is an employee of
anofi-Aventis.i
Manuscript received July 26, 2004; revised manuscript received November 13,
004, accepted November 16, 2004.he long-term cost-effectiveness of clopidogrel by translat-
ng the reduction in primary fatal and nonfatal events
bserved with clopidogrel in the CURE trial into estimates
f gains in life expectancy to arrive at an estimate of the
ncremental cost/LYG.
ETHODS
esign of the CURE trial. The CURE study, a large,
ulticenter randomized controlled trial, has been described
reviously in detail (1). Briefly, 12,562 patients were re-
ruited from December 1998 to September 2000 at 482
enters from 28 countries. Patients were eligible if they were
ospitalized within 24 h of onset of symptoms indicative
f acute coronary syndrome (ACS) and did not have
ignificant ST-segment elevation. Patients were assigned
andomly to clopidogrel (loading dose of 300 mg followed
y 75 mg per day) or a placebo for an average period of
ine months. All patients received acetylsalicylic acid (75 to
25 mg daily). The primary clinical outcome was a com-
osite of cardiovascular death, nonfatal MI, or stroke. All
atients in both arms received conventional treatments,
ncluding thrombolytic agents, heparin, diuretics, antiangi-
al therapy, antihypertensive medication, cholesterol-
educing agents, and glycoprotein IIb/IIIa antagonists dur-
ng percutaneous coronary intervention (PCI). The CURE
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ites and analytic centers and complies with the Helsinki
rotocol for protection of human subjects.
conomic analysis plan and assessment of cost. The
conomic analysis plan was to compare the costs of the two
reatment arms and, if the clopidogrel arm was more costly as
ell as more effective, to perform an incremental cost-
ffectiveness analysis (3,4). Costs included in the analysis are
irect medical care costs for hospitalizations and the cost of
lopidogrel. No data are available from the CURE trial to
alculate indirect costs due to lost productivity. Cost after the
rst year and life expectancy were discounted 3% annually. The
nalysis uses U.S. dollars as the unit of analysis but uses
esource use and clinical outcomes from all 12,562 patients.
Cardiovascular health care resource use associated with
he index, and all follow-up hospitalizations were recorded
rospectively, including diagnostic tests, therapeutic proce-
ures, and medications. Ambulatory care, including outpa-
ient diagnostic procedures and testing (other than coronary
ngiography), was not recorded. Because most resource-
ntensive procedures and tests are performed while patients
re hospitalized, it is likely that most of the major compo-
ents of health care resource use were collected. Possible
xceptions would include same-day testing not requiring
ospitalization, such as nuclear imaging studies or echocar-
iograms, and nursing home and rehabilitation stays after
troke. The use of medication other than study drug was not
ound to differ between the study arms. The use of open-
abel clopidogrel and adherence to double-blind treatment
ere recorded during hospitalizations and at periodic
ollow-up visits.
The initial and subsequent hospitalizations were assigned
diagnosis-related group (DRG), as used in the Medicare
rogram in the U.S., by coders who were blinded to
reatment group. Noncardiovascular follow-up hospitaliza-
ions were recorded but not included in this analysis because
heir frequency was rare and because they were distributed
qually between treatment arms. Costs for each DRG were
stimated using average Medicare reimbursement rates
5,6), which were obtained from the Medicare Part A data
le (7), and average private payer reimbursement rates,
hich were obtained from the MEDSTAT database (5,8).
Abbreviations and Acronyms
ACS  acute coronary syndrome
CURE  Clopidogrel in Unstable angina to prevent
Recurrent Events trial
DRG  diagnosis-related group
ICER  incremental cost-effectiveness ratio
MI  myocardial infarction
LOS  length of stay
LYG  life-year gained
PCI  percutaneous coronary intervention
QALYs  quality-adjusted life-yearsblended MEDSTAT-Medicare cost estimate was gener- cted by applying MEDSTAT costs to the CURE trial
atients younger than 65 years of age and Medicare costs
o patients older than 65 years of age. The MEDSTAT
stimates include professional costs; for Medicare, profes-
ional costs were calculated as a percentage of hospital costs
y DRG, according to the method of Mitchell et al. (9).
osts beyond the trial period were estimated as the average
er capita participant Medicare reimbursement of $4,370 in
001 (10).
ife expectancy estimation. Life expectancy for patients
ith and without nonfatal events was estimated from two
ndependent sources: the Framingham Heart Study (11,12)
nd the Saskatchewan Health database (13). For the latter,
urvival data on all 15,956 patients with acute MIs as
efined by the International Classification of Diseases-9th
evision-code 410, from the years 1990 to 1995 with
ollow-up through the end of 2000, were analyzed using
ublished methods (13). Briefly, mean survival beyond the
nd of the trial was estimated by integrating the survival
urves, adjusted for various patient characteristics, including
xperience of specific subsequent ischemic events (13,14).
ox proportional hazards survival models for each time
eriod were derived for patients with age, diabetes, previous
I, previous ischemic stroke, previous coronary artery
ypass graft, and hypolipidemic use as covariates (13–18).
he cumulative survival functions over the course of time
ere derived by applying the hazard functions in sufficiently
rief intervals that the hazard can be assumed to be constant
uring the period.
For both the Framingham Heart Study and Saskatchewan
ealth database, gender and age-specific estimates of life-years
ost due to events were obtained by subtracting life expectancy
stimates for individuals with a given event pattern from life
xpectancy estimates for individuals with no events (14). These
stimates were then applied to the CURE trial patient popu-
ation. For patients who experienced multiple events of differ-
nt types during the trial, lost life expectancy was estimated
ssuming a hierarchy of death, stroke, and MI. It was assumed
hat clopidogrel would be stopped at the end of the trial and
hat there would be no further reduction (or increase) in
onfatal events between the two arms. As a sensitivity analysis,
ardiovascular death (as used in the clinical endpoint) rather
han all-cause death (the primary analysis for the economic
tudy) was used to estimate years of life lost. The difference
etween treatment groups in average life-years lost because of
vents (placebo clopidogrel) yields an estimate of LYG with
lopidogrel. Variability associated with these lost life expect-
ncy estimates was not accounted for in the cost-effectiveness
nalyses.
stimation of cost-effectiveness. The cost-effectiveness of
lopidogrel was expressed as the incremental cost-
ffectiveness ratio (ICER), which is the added cost in the
lopidogrel arm divided by LYG. Bootstrap methods (5,000
eplicates) were used to estimate the 95% CIs for both cost
nd LYG with clopidogrel (19). Sensitivity analyses in-
luded reducing life expectancy gains by 50% and then by
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Cost-Effectiveness of Clopidogrel in ACS March 15, 2005:838–450%, adding estimated costs associated with bleeding,
dding costs due to added years of life, and quality adjusting
urvival. The impact of bleeding on cost could not be
alculated directly because the costing was based on DRGs,
hich would not necessarily be affected by bleeding. There-
ore, the impact of bleeding on hospital length of stay
LOS) was estimated using CURE trial data, and the
oncomitant cost increase was estimated assuming an aver-
ge cost of $2,000 per day.
ESULTS
ummary of the clinical data. No differences existed
etween treatment groups in age, gender, or MI either at
resentation or in previous history, diabetes, or hyperten-
ion (Table 1). The clinical outcome, the composite of
ll-cause death, MRI, or stroke by 12 months follow-up was
able 1. Clinical Summary
Baseline Characteristics
Clopidogrel
(n  6,259)
Placebo
(n  6,303) p Value
ge 64  11 64  11 0.7448
omen 39% 38% 0.6450
I at presentation 26% 26% 0.6098
revious MI 32% 32% 0.6314
iabetes 22% 23% 0.5920
ypertension 60% 58% 0.0168
linical outcomes for
economic study
9.3% 11.4% 0.0001
Death (any cause) 5.8% 6.2% 0.2779
MI 5.2% 6.7% 0.0004
Stroke 1.2% 1.4% 0.3532
leeding, major, or
life-threatening
3.70% 2.70% 0.0015
Major 1.5% 0.9% 0.002
Life threatening 2.1% 1.7% 0.10
Major  life-threatening 0.1% 0.1% 1.00
inor bleeding 5.1% 2.4% 0.0001
I  myocardial infarction.
able 2. DRGs, Associated Costs, and Distribution of DRGs for
DRG
DRG
Code
MEDSTAT Cost
($)
nstable angina 140 4,295
nstable angina with angiography 124 11,947
I—expired 123 15,441
I—simple 122 12,132
I—complex 121 15,198
ther cardiovascular 120 23,109
CI 112 14,209
ABG surgery 107 36,080
CI  CABG 106 46,660
troke 14 11,776
hest pain 143 3,914
onfatal cardiac arrest 129 12,380
eart failure 127 8,142
ther CT surgery 108 52,148ABG  coronary artery bypass grafting; CT  cardio-thoracic; DRG  diagnosis-relatignificantly lower in the clopidogrel group, 9.3% versus
1.4%, p  0.001, relative risk 0.80 (95% CI 0.72 to 0.90).
here were trends toward a reduction in death from any
ause as well as stroke. There was a significant reduction in
I. Bleeding was increased with clopidogrel. Hospitaliza-
ions by treatment group for each DRG assignment, and
heir associated unit costs are shown in Table 2.
stimation of LYG. Using both the Framingham Heart
tudy and Saskatchewan Health database, there were trends
oward life expectancy gains with clopidogrel as a result of
he reduction in each of the individual events of death, MI,
nd stroke (Table 3). Overall, patients in the clopidogrel
rm were estimated to have gained an average of 0.0699
ife-years relative to patients in the control arm using
ramingham data and 0.0682 life-years using Saskatche-
an. Overall nine-month mortality for Saskatchewan pa-
ients with characteristics similar to the CURE placebo
roup was 7.7%, compared with 5.9% within CURE.
ortality at nine months in the CURE trial was 4.0% in
atients who did not suffer and MI and 26% in patients who
id suffer an MI between randomization and nine months
hazard ratio 5.74, p  0.0001 adjusted for age, gender,
revious MI, diabetes, smoking). This result compares with
nine-month mortality of 3.7% without an MI and 25%
ith an MI using Saskatchewan data. Similarly mortality at
ine months in the CURE trial was 5.1% in patients who
id not suffer a stroke and 23% in patients who did (hazard
atio 4.3, p  0.0001 corrected for age, gender, previous
I, diabetes, smoking).
n-trial costs. Exclusive of clopidogrel costs, initial hospi-
alization, rehospitalization, and total costs tended to be
ower in the clopidogrel arm (Table 4). On the basis of
edicare costs, total costs were significantly higher in the
lopidogrel group, whereas for MEDSTAT and the Medi-
are/MEDSTAT blend, the differences were not signifi-
ant. Total costs based on Medicare for subgroups defined
ial and Subsequent Hospitalizations
icare Cost
($)
Initial Hospitalization
(Frequency)
Subsequent
Hospitalization
(Frequency)
Clopidogrel Placebo Clopidogrel Placebo
3,542 2,759 2,710 738 688
8,010 742 684 489 479
7,651 44 48 54 47
6,337 1,247 1,231 1 3
8,643 140 163 123 156
0,897 44 56 20 9
0,342 793 876 486 475
9,127 479 519 436 455
8,850 6 11 3 3
6,493 5 5 46 62
3,447 0 0 144 210
5,627 0 0 7 4
5,449 0 0 195 186
9,034 0 0 19 25Init
Med
1
1
2
3
2ed group; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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March 15, 2005:838–45 Cost-Effectiveness of Clopidogrel in ACSccording to age, gender, diabetes, and previous MI are
hown in Figure 1. Results for all subgroups resemble those
or the total population, with trends toward slightly higher
osts in the clopidogrel arm.
ost-effectiveness. Using Framingham study-based esti-
ates, not including costs beyond the trial period, the ICERs
anged from $4,833 with MEDSTAT to $6,318 with Medi-
are, with more than 90% of bootstrap estimates $50,000/
YG (Table 5). Similarly, using Saskatchewan data-based
stimates, ICERs ranged from $4,953 with MEDSTAT to
6,475 with Medicare, with more than 95% of bootstrap
stimates $50,000/LYG. The ICERs are systematically
igher using the average Medicare cost per year to estimate
osts beyond the trial period. A plot of the bootstrap-derived
oint distribution of cost and effectiveness differences on the
asis of Medicare costing and Framingham-based effectiveness
stimates is shown in Figure 2, and cost-effectiveness accept-
bility curves on the basis of Medicare, MEDSTAT, and the
lended costing approaches and Framingham life expectancy
stimates are shown in Figure 3. The three costing approaches
ielded similar results, with most of bootstrap-derived cost-
ffectiveness estimates $15,000/LYG. Incremental cost-
ffectiveness ratios for subgroups, on the basis of Medicare
Table 3. Life-Years Lost Attributable to Cardi
Clopidogrel Placebo
Framingham
Death 0.4563 0.4920
MI 0.0208 0.0305
Stroke 0.0557 0.0802
Total 0.5327 0.6026
Saskatchewan
Death 0.3044 0.3343
MI 0.0255 0.0336
Stroke 0.0611 0.0913
Total 0.3910 0.4592
CI  confidence interval; MI  myocardial infarction.
Table 4. Costs
Clopidogrel P
Initial hospitalization
Medicare $7,680
MEDSTAT $10,953 $
Medicare/MEDSTAT blend $9,291
Rehospitalization
Medicare $4,557
MEDSTAT $6,189
Medicare/MEDSTAT blend $5,284
Total, exclusive of clopidogrel
Medicare $12,237 $
MEDSTAT $17,142 $
Medicare/MEDSTAT blend $14,575 $
Clopidogrel costs $782
Total, including clopidogrel
Medicare $13,019 $
MEDSTAT $17,924 $
Medicare/MEDSTAT blend $15,357 $CI  confidence interval.osting and both Framingham and Saskatchewan life expect-
ncy estimates, are shown in Figure 4. Results for most of the
ubgroups are similar to the overall estimate, with the excep-
ion of women, for whom the ICER was higher. Because of
our more noncardiovascular deaths in the clopidogrel arm,
CERs for women are considerably lower when cardiovascular
eath was considered in the estimation of life-years lost (along
ith nonfatal stroke and MI), rather than all-cause death
$29,130 on the basis of Framingham and Medicare, $49,369
n the basis of Saskatchewan and Medicare). For all other
ubgroups there was little difference in ICERs on the basis of
ll-cause versus cardiovascular death.
ensitivity analyses. These analyses required the use of
xternal databases to project life expectancy beyond the end
f the trial. The life expectancy gain with clopidogrel may
e either smaller or larger than projected. If the estimated
ain in life expectancy is only half of that projected, using
he blended costing approach and Framingham life expect-
ncy estimates, the ICER would be $9,820, with 91.9% of
ootstraps samples $50,000/LYG; on the basis of
askatchewan data, it would be $10,065, with 96.7%
$50,000/LYG. If the life expectancy gain is just 20% of
hat projected, the ICER would be $24,549, with 77.7%
ular Events
fe-Years Gained
ith Clopidogrel
95% CI for Life-Years
Gained With Clopidogrel
0.0357 0.0303 to 0.1106
0.0097 0.0009 to 0.0199
0.0245 0.0108 to 0.0397
0.0699 0.0077 to 0.1440
0.0299 0.0185 to 0.0822
0.0081 0.0027 to 0.0190
0.0302 0.0176 to 0.0440
0.0682 0.0122 to 0.1190
o  (Clopidogrel  Placebo) 95% CI for 
8 $238 483 to 10
5 $312 628 to 14
6 $295 576 to 37
4 $86 426 to 252
6 $117 580 to 340
3 $128 512 to 272
2 $325 722 to 45
0 $428 947 to 53
8 $423 880 to 25
6 $766 757 to 776
8 $442 62 to 820
6 $338 165 to 827
4 $343 90 to 784ovasc
Li
Wlaceb
$7,91
11,26
$9,58
$4,64
$6,30
$5,41
12,56
17,57
14,99
$1
12,57
17,58
15,01
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Cost-Effectiveness of Clopidogrel in ACS March 15, 2005:838–45$50,000/LYG on the basis of Framingham, and $25,161,
ith 81.8% $50,000/LYG based on Saskatchewan.
For hospitalizations in which a major bleed occurred,
OS increased 5.94 days. In hospitalizations in which a
ife-threatening bleed occurred, LOS increased 4.57 days,
nd a major and life-threatening bleed 9.91 days. Combin-
ng the LOS data with the bleeding incidence from Table 1
dds an incremental average of 0.05392 days to LOS. If an
dditional day in the hospital, independent of the DRG
ssignment, costs $2,000 per day, then incremental bleeding
ue to clopidogrel adds $108 to the average cost per patient.
his would increase the ICER for Framingham, using
edicare costing, from $6,318 to $7,868.
Utility was not measured in CURE and, thus, we could
ot calculate quality-adjusted life-years (QALYs) directly
sing patient-level data. Because there were more nonfatal
igure 1. Total costs by treatment group overall and for subgroups based
onfidence interval; MI  myocardial infarction.
able 5. Cost Effectiveness
 Cost  Life-Ye
o direct costs beyond trial period
ramingham
Medicare $442 0.0699
MEDSTAT $338 0.0699
Blend $343 0.0699
askatchewan
Medicare $442 0.0682
MEDSTAT $338 0.0682
Blend $343 0.0682
ncluding direct costs beyond trial period*
ramingham
Medicare $639 0.0699
MEDSTAT $535 0.0699
Blend $541 0.0699
askatchewan
Medicare $637 0.0682
MEDSTAT $534 0.0682
Blend $540 0.0682Assuming $4,370 annual follow-up medical cost.
ICER  incremental cost-effectiveness ratio; LYG  life year gained.vents in the placebo arm, it might be reasonable to expect
tility to be higher in the clopidogrel arm, rendering results
escribed above conservative. However, if utility is1.0 but
qual for both arms, the ICER in terms of cost per QALY
ained would be higher than the cost per LYG estimate. If
tility was 0.80 in both arms (20), then the ICER using
ramingham life expectancy and Medicare costs would be
7,898/QALY gained. If costs in added years of life were
lso included, the ICER would be $11,430/QALY gained.
ISCUSSION
or patients with ACS, antiplatelet therapy with clopi-
ogrel is cost-effective, with ICERs ranging from $4,910
o $6,473/LYG, and with 90% of bootstrap samples
$50,000/LYG for all models (21,22). These results were
edicare costs. Solid bars  placebo; hatched bars  clopidogrel. CI 
ICER % Dominant % Dominated % <50,000/LYG
$6,318 1.20% 4.00% 93.9%
$4,833 9.30% 4.00% 93.9%
$4,910 6.90% 4.00% 94.5%
$6,475 1.20% 0.70% 97.7%
$4,953 9.30% 0.70% 98.1%
$5,032 6.90% 0.77% 98.3%
$9,144 0.60% 4.00% 92.8%
$7,654 2.70% 4.00% 93.4%
$7,742 2.00% 4.00% 93.4%
$9,343 0.1% 0.70% 97.0%
$7,833 2.3% 0.70% 97.6%
$7,921 1.5% 0.70% 97.5%ars
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March 15, 2005:838–45 Cost-Effectiveness of Clopidogrel in ACSonsistent for the three DRG-based approaches to costing
ospitalizations and the two approaches to estimating the
ain in life expectancy by the prevention of events. The
esults remained favorable when estimated direct medical
are costs associated with increased life expectancy in the
lopidogrel arm are included and when estimated quality-
f-life adjustments were incorporated. The ICERs were
avorable for nearly all subgroups considered. Only in
omen were estimated ICERs $50,000 per LYG, due in
arge part to a trend toward more noncardiovascular deaths
igure 2. Scatterplot of the joint distribution of cost and effectiveness diffe
xpectancy estimates.igure 3. Cost-effectiveness acceptability curves based on Medicare, MEDST
stimates.n women in the clopidogrel arm. Such results highlight the
ifficulty in drawing inferences with respect to both clinical
fficacy and cost-effectiveness in underpowered clinical trial
ubgroups (23). Incremental cost-effectiveness ratios for
omen became more attractive when life-year estimates
ere made on the basis of cardiovascular death, which was
prespecified end point in the CURE trial.
Antiplatelet therapy with aspirin and adenosine diphos-
hate blockers has been shown to be beneficial in the
reatment of vascular disease and to prevent thrombosis
in the cost-effectiveness plane using Medicare costs and Framingham lifeAT, and Medicare/MEDSTAT costs, and Framingham life expectancy
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Cost-Effectiveness of Clopidogrel in ACS March 15, 2005:838–45fter PCI. In the CURE trial, clopidogrel therapy for up to
ne year was shown to prevent cardiovascular events in
atients presenting with ACS (1). There was a slightly
ncreased risk of non–life-threatening bleeding with clopi-
ogrel, which largely was associated with procedures within
he first 30 days after randomization, and managed success-
ully (24). The beneficial effects of clopidogrel also were
ound in the subset of patients who underwent PCI in the
CI-CURE study (25) and in Clopidogrel for the Reduc-
ion of Events During Observation (CREDO) trial (26).
The present analysis builds on an assessment of short-
erm cost-effectiveness conducted from the perspective of
he United Kingdom, U.S., Sweden, France, and Canada on
he basis of results from the CURE trial (2). In that study,
ost per primary outcome event avoided with clopidogrel
as £10,366 in United Kingdom, $22,484 in the U.S., SKr
27,951 in Sweden, €16,186 in France, and C$7,973 in
anada (2). In addition, a Swedish study suggested that
lopidogrel is cost-effective in cost/LYG (27). One addi-
ional analysis, using decision analytic methodology, sug-
ested that multiyear therapy with clopidogrel would only
e cost-effective in patients who cannot tolerate aspirin (28).
A strength of the present analysis is that it was performed
ith patient-level data directly from the CURE trial. More-
ver, as a randomized comparison, the assessment of both
ffectiveness and cost reflect the actual exposure to treatments
ndependently of selection bias. In the CURE trial, concomi-
ant medicine use reflected care consistent with American
ollege of Cardiology/American Heart Association ACS
uidelines; in particular, statins, angiotensin-converting en-
yme inhibitors and beta-blockers. Thus, the CURE trial
erves as a contemporary evaluation of the effectiveness of
lopidogrel and aspirin versus aspirin and placebo.
tudy limitations. One limitation of our study is that the
URE trial was a multinational trial and our approach of
igure 4. Incremental cost-effectiveness ratio (ICER) both overall and for s
xpectancy estimates. *ICER in women considering life expectancy gains due
onfatal stroke and myocardial infarction [MI]): $29,130 on the basis of Frampplying U.S. costs to trial-wide hospitalizations on the Casis of DRGs does not fully account for possible differences
n treatment practices and resource use between countries or
ealth care systems. If a large proportion of patients come
rom countries for which the threshold for hospitalization
iffers considerably from that in the U.S., the difference in
osts between treatments may be underestimated or overes-
imated. However, unless within a DRG the costs are
igher in one treatment arm, this approach to costing
ospitalizations should yield unbiased overall cost estimates
nd, in fact, should reduce unwanted variability in the
valuation of cost differences attributable to treatment.
No outpatient treatment, rehabilitation, or nursing home
esource use was collected in the CURE trial, and associated
osts are therefore excluded from this analysis, as well as
ndirect costs associated with lost productivity. However,
hose costs might be expected to be higher in the placebo
rm because of the higher in-trial nonfatal event rate, which
ould result in our estimates being conservative.
The costs of bleeding were not directly measured in the
URE trial. However, when analyzed using LOS as a proxy
or cost, the effect on the ICER was modest. This sensitivity
nalysis may double count some of the cost of bleeding
ecause some of this cost may be accounted for by DRG
ssignment, thus increasing the ICER.
External databases were used to estimate life expectancy.
ultiple improvements in medical care have extended life of
atients with vascular disease such that a database like
ramingham may not adequately reflect these improvements.
owever, the Saskatchewan patient sample was based on index
ospitalizations occurring between 1990 and 1995, yielding
imilar life expectancy results to Framingham. That the two
xternal databases yielded similar results offers reassurance that
he estimates used in this analysis are reasonable. More
mportantly, although nine-month mortality was actually
lightly higher in the Saskatchewan patient sample than in the
ups based on Medicare costs and both Framingham and Saskatchewan life
prevention of cardiovascular death rather than all-cause death (in addition to
am; $49,369 on the basis of Saskatchewan. LYG  life-year gained.ubgroURE trial, mortality rates with and without an MI were
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March 15, 2005:838–45 Cost-Effectiveness of Clopidogrel in ACSimilar between the two sources. Although the Saskatchewan
ata still may not perfectly reflect current prognosis during a
onger term, a greater hazard of death without contemporary
herapy would mean the projected life expectancy would be
horter, rendering these results conservative. Similarly, the data
rom Saskatchewan was all from MIs, which may have a higher
azard long term than the ACS patients in the CURE trial,
gain rendering the present analysis conservative. In addition,
here is little doubt that events do predict future increased
ortality (29,30). If the prognostic importance of events in the
URE trial was just 20% of that in Framingham and
askatchewan, the ICERs would still be reasonable. The
mpact of an MI occurring in the CURE trial between
andomization and nine months follow-up was large, with a
ortality of 26.3% versus 4.0% in patients suffering versus not
uffering an MI; this suggests that these events are worth
reventing.
onclusions. From a U.S. societal perspective, clopidogrel
or up to one year in the setting of ACS is cost-effective
ccording to commonly used benchmarks.
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